# Palacaparib

Source: https://onco.cc/drugs/palacaparib/  
OnCo record `palacaparib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Palacaparib is an experimental small-molecule drug from AstraZeneca in phase 2 trials for ovarian cancer, non-small-cell lung cancer and endometrial cancer, aimed at PARP.

## Summary

Palacaparib (AZD9574) is a small-molecule drug developed by AstraZeneca. Its target is PARP (the sponsor names PARP). The sponsor states: An oral PARP inhibitor that blocks PARP enzyme activity, preventing DNA repair in cancer cells, particularly tumours with homologous recombination deficiency. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in ovarian cancer, non-small-cell lung cancer and endometrial cancer. The largest, NCT05797168, plans to enrol 602 participants with primary completion expected 2028-08-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: AZD9574
- Modality: small molecule
- Mechanism: An oral PARP inhibitor that blocks PARP enzyme activity, preventing DNA repair in cancer cells, particularly tumours with homologous recombination deficiency.

## Sources

- ClinicalTrials.gov: trials of Palacaparib: https://clinicaltrials.gov/search?intr=AZD9574

## Connected records

- cancers: [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies](https://onco.cc/trials/nct05123482/), [Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors](https://onco.cc/trials/nct05797168/), [Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct07590934/), [Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer](https://onco.cc/trials/nct07181161/), [Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies](https://onco.cc/trials/nct05417594/)

---
JSON: https://onco.cc/api/v1/entities/palacaparib.json